HIV Vaccine Info-line
080 VACCINE

 

Publications and conference presentations 2004

SAAVI Directorate

Publications

  1. Tucker TJ, Mazithulela G. Development of an AIDS vaccine: perspective from the South African AIDS Vaccine Initiative. BMJ 2004; 329 (7463): 454 - 456.
  2. Reporting back on World AIDS Vaccine Awareness Day. Southern African Journal of HIV Medicine 2004; 15 : 42 - 43.

Presentations

Conferences

  1. Levendal E, Smit T. Considering Gender, Race and Age in preparing communities for the HIV and AIDS Vacine Development Process. AIDS Vaccine 2004, Lausanne, 1 - 2 September.
  2. Levendal E. Community Preparedness: Towards a common understanding. AIDS Vaccine 2004, Lausanne, 1 - 2 September 2004.

Invited presentations have included:

  • Presentation to the Norwegian Standing Committee on Health and Social Services - 21 January 2004
  • Cape Technikon AIDS Committee - 15 April 2004
  • Higher Education Sector AIDS Programme - 11 June 2004
  • Technikons and Universities AIDS Representatives - 19 August 2004
  • Employees Professional Assistance Conference - 2 September 2004
  • Presentations on SAAVI CPP in Kenya, Uganda & Nigeria
  • Correctional Services, Pollsmoor Prison - 7 October 2004
  • Keynote address Astra Zeneca Open Day, University of Stellenbosch, October 2004.
  • The SAAVI model. Workshop on PPPs: are they the answer, University of Edinburgh, Edinburgh, December 2004.

Press releases

  • Implats to fund vaccine development - 18 May 2004
  • Transnet comes on board to fund HIV/AIDS vaccine development - 18 May 2004
  • Nelson Mandela Foundation and SAAVI announce partnership - 12 August 2004
  • Ukukhanya photographic exhibition - 1 December 2004

University of Cape Town

Publications

  1. Gottlieb GS, Nickle DC, Jensen MA, Wong KG, Grobler J, Li F, Liu SL, Rademeyer C, Learn GH, Abdool Karim SA, Williamson C, Corey L, Mragolick JB, Mullins JI. Dual HIV-1 infection associated with rapid disease progression. Lancet 2004; 363, 21 February 2004.
  2. Jaffray A, Shephard E, van Harmelen J, Williamson C,Williamson AL, Rybicki EP. HIV-1 subtype C Gag VLP boost substantially improves the immune response to a subtype C Gag DNA vaccine in mice. J Gen Virol 2004; 85 (Pt 2): 409-413.
  3. Grobler J, Gray CM, Rademeyer C, Seoighe C, Ramjee G, Abdool Karim S, Morris L, Williamson C. The incidence of HIV-1 dual infection and its association with increased viral load set point in a cohort of subtype C infected female sex-workers. JID 2004. In press.
  4. Rademeyer C, van Harmelen JH, Ramjee G, Abdool Karim SS, Williamson C. Heterosexual transmission of multiple highly conserved viral variants in HIV-1 subtype C infected seronegative women. AIDS 2004. In press.
  5. Martin D, Williamson C. Human Immunodeficiency Virus - One of nature’s greatest evolutionary machines. S Afr J Science . In press.
  6. Martin D, Williamson C.Origin, diversity and spread of HIV-1. In: Abdool Karim SS, ed. HIV/AIDS in South Africa, Cambridge University Press, 2004.
  7. Martin DP, Posada D,Williamson C. RDP2: Recombination detection and analysis from sequence alignments. Bioinformatics. In Press.
  8. Martin DP, Posada D, Williamson C.An improved bootscanning method for automated detection and description of recombination events in HIV-1 genomes . AIDS and Human Retroviruses. In Press.

Conference presentations

  1. Van Harmelen JH, Bodley M, Adams C, Burgers W, Blanckensee T, Williamson C, Quality Management System (QMS) for preclinical potency evaluation of DNA vaccines for phase I clinical trials. AIDS Vaccines 2004, Lausanne, Switzerland, 30 August to 1 September 2004.
  2. Washington, Acute Infection Meeting two posters:
    HIV-1 viral loads in early HIV-1 subtype C infection and long-term follow-up. (Koleka P. Mlisana, Van Loggerenberg F, Gray CM, Williamson C, Morris L, Ramjee G, Abdool Karim S).
    High risk cohorts - Challenges and Lessons in Recruitment and Retention of a cohort of Female Sex workers (FSWs) in and around Durban, South Africa (Van Loggerenberg F, Mlisana K, Williamson C & Abdool Karim S)
  3. International Microbicide Conference , London, March 2004 and UCT research day:
    Characterisation of recently transmitted HIV-1 variants in subtype C infected women (Rademeyer C, Grobler j, van Harmelen J,  Ramjee G,  Abdool-Karim S, Williamson C).

HAVEG

Articles in peer-reviewed journals

Book chapters

  • Stobie, M.L., Strode, A., & Slack, C. (In press). The dilemma of enrolling children in HIV vaccine research in South Africa: What is in a child’s best interest?. Chapter in AIDS in Africa . A.A. Van Niekerk, & L.M. Kopelman (Eds.). Cape Town : David Philip/New Africa Books.
  • Lindegger, G. (2005). Informed consent in HIV Vaccine trials. In P. Kahn (Ed.) AIDS vaccine handbook: Global perspectives (2 nd edition). New York : AIDS Vaccine Ad vocacy Coalition (AVAC).
  • Wassenaar, D., & IJsselmuiden, C. (In Press). Commentary: Obligations to provide care and information to participants harmed in the course of a multi-center vaginal microbicide trial in Asia and Africa. In J,V. Lavery, E. Wahl, C. Grady, & E.J. Emanuel. (Eds).Ethical issues in international biomedical research: A case book. New York: Oxford University Press, 2005.
  • Slack, C., Stobie, M., & Barsdorf, N. (In Press). Commentary: Phase 1 trials of preventive HIV vaccines in South Africa: Access to treatment for trial participants who become infected during the course of a trial. In In J,V. Lavery, E. Wahl, C. Grady, & E.J. Emanuel. (Eds).Ethical issues in international biomedical research: A case book. New York: Oxford University Press, 2005.
  • Stobie, M.L., Strode, A., & Slack, C. (In Press). The dilemma of enrolling children in HIV vaccine research in South Africa: What is in a child's best interest?. In A. A. Van Niekerk, & L.M. Kopelman, (Eds). AIDS in Africa. Cape Town: David Philip/New Africa Books.
  • Lindegger, G. (2005). Informed consent in HIV Vaccine trials. In Kahn, P. (Ed) AIDS vaccine handbook: Global perspectives, (2nd ed.) pp. 109 - 116. New York: AIDS Vaccine Advocacy Coalition (AVAC).

Reports & Lay publications

  • Wassenaar, D.R., Barsdorf, N.W., and Richter, L.M. (2005). Gender and HIV vaccine trials: Ethics and Social science issues. Harvard Health Policy Review (in press).
  • Van Loon, K., Lindegger G., and Slack C. (2002). Informed consent: The experiences of clinical trial researchers in South Africa. 14th International AIDS Conference Proceedings. Monduzzi AIDS 2002 publication.
  • Lindegger, G. & Bull, S (2002). Ensuring valid consent in a developing country context. http://www.scidev.net/dossiers/ethics/erpolicy_lindegger_bull.html
  • Richter, L (2001). Response to Nuffield Foundation's Public Consultation on the Ethics of Health-Care related Research in Developing Countries.
  • Lindegger, G. (2000). Cross cultural issues in the implementation of informed consent in HIV vaccine trials. XIII International AIDS Conference Proceedings. Monduzzi AIDS 2000 publication.
  • Lindegger, G. & Slack, C. (2002). Making sure HIV vaccine clinical trials are ethically sound and culturally sensitive: A brief report on the HIV AIDS Vaccines Ethics Group. AIDS Bulletin, July, 19-20. Medical Research Council.
  • Slack, C, Lindegger, G, Wassenaar, D (2002). The ethical issues in clinical trials. Newletter: Lawyers for Human Rights: Yands'ulwazi; July , 3-5.
  • Wassenaar, D.R, and Richter, L.M (2000). Women at the centre of the relationship between science and ethics in HIV/ AIDS vaccine trials in developing countries. AIDS Legal Quarterly, December, 6-7.
  • Slack, C (2000). Knowing and doing the right things: Ethical issues in HIV AIDS vaccine trials. AIDS Legal Quarterly, December, 11.
  • HAVEG (2001). Ethical issues in HIV vaccine trials. Department of Health HIV AIDS and TB newsletter.

Presentations at conferences and capacity building workshops

  • Stobie, M. (2005). Social and ethical aspects of vaccine and drug delivery” A Time to Heal: Cracking Africa's Killer Diseases. Africa Genome Education Institute. Nairobi, Kenya, 21-24 March.
  • Stobie, M., Slack, C., Milford, C., Lindegger, G., Wassenaar, D., Strode, A., & IJsselmuiden, C. (2005). Provision of HIV treatment in HIV vaccine trials: An ethical analysis Paper presented at WHO Institute for Vaccine Research consultation on Ethical Considerations related to the Provision of care and Treatment in vaccine Trials. Zomba, Malawi, 15-16 March.
  • Slack, C. (2005). Ancillary care. Paper presented in special session on ancillary care. Paper presented at EU/University of Bergen & SARETI Conference on Ethical Aspects of Clinical Research in Developing Countries. Umhlanga Rocks, Durban, 28 February - 2 March .
  • Wassenaar, D., & Slack, C. (2004). Access to treatment in HIV vaccine trials: The South African case. Presented at First NIH/AMANET Advanced Course in research Ethics, Zanzibar, 1-3 December.
  • Lindegger, G., Van Loon, K., Maxwell, J., Slack, C., & Milford, C. (2004). Experiences of informed consent in a culturally diverse context. Paper presented at the 7 th World Congress of Bioethics, University of New South Wales, Sydney, Australia, 9-12 November.
  • Lindegger, G., Milford, C., & Slack, C. (2004). The development and comparison of methods to assess understanding for informed consent for phase I HIV vaccine trials. Paper presented at the 7 th World Congress of Bioethics, University of New South Wales, Sydney, Australia, 9-12 November 2004.
  • Stobie, M., & Lindegger, G. (2004). Children's capacity for altruistic choices: Implications for the enrollment of children in HIV vaccine trials. Paper presented at the 7 th World Congress of Bioethics, University of New South Wales, Sydney, Australia, 9-12 November 2004.
  • Milford, C., Lindegger, G., & Slack, C. (2004). Developing tools to “test “ understanding in HIV vaccine trials in South Africa . Poster at the XV International AIDS Conference, Bangkok Thailand 11-16 July.
  • Strode, A., & Slack, C. (2004). Ethical-legal complexities in adolescent participation in HIV vaccine trials. A South Africa case study. Paper presented at the XV International AIDS Conference, Bangkok, Thailand, 11-16 July.
  • Slack, C., Strode, A., & Kruger, M. (2004). Developing guidelines for the South African Medical Research Council on HIV vaccine research. Paper presented at the Nuffield Council on Bioethics workshop on the ethics of research related to health-care in developing countries, Cape Town, 12-14 February.
  • Stobie, M. (2004). Enrolling children in HIV vaccine trials: Balancing justice and beneficence. Paper presented at the Philosophical Society of South Africa Conference, Fernhill, KwaZulu-Natal, 19 January.
  • Stobie, M., Slack, C., & Barsdorf, N. (2004). Access to treatment for HIV infection for phase I HIV vaccine trial participants: Obligations in a non-ideal world. Paper presented at the Ethics Society of South Africa's Inaugural conference, Johannesburg, 29 March.
  • Slack, C., Stobie, M., Lindegger, G., Milford, C., Wassenaar, D., Strode, A., & IJsselmuiden, C. (2003). Access to treatment for participants who become infected during the course of an HIV vaccine trial. Paper presented at the NIH Third Bioethics Conference in Africa, Kampala, Uganda, 21 March.
  • Slack, C., Stobie, M., Lindegger, G., Milford, C., Wassenaar, D., Strode, A., & IJsselmuiden, C. (2003). Ethical considerations in HIV vaccine trials in South Africa: A focus on standard of care . Paper presented at the 23 rd International Congress of Chemotherapy, Durban, South Africa, 7-9 June.
  • Strode, A., Slack, C., Milford, C., & Stobie, M. (2003). A critical evaluation of South Africa's ethical-legal framework. Paper presented at the First South African AIDS Conference, Durban, South Africa, 3-6 August.
  • Milford , C., Wassenaar, D.R., Slack, C., Strode, A., & Khan, N (2003). Identifying resources and needs of research ethics committees in Africa in preparation for HIV vaccine trials. Paper presented at First South African AIDS Conference, Durban, South Africa, 3-6 August.
  • Slack, C., Stobie, M., Lindegger, G., Milford, C., Wassenaar, D., Strode, A., & IJsselmuiden, C. (2003). Standard of care in international trials of HIV vaccines and Microbicides. Paper presented at the International Consultation on ethical issues in the clinical testing of Microbicides, 23-24 October.
  • IJsselmuiden, C. (2003). International research ethics and key debates. Paper presented at the International Consultation on ethical issues in the clinical testing of Microbicides, 23-24 October.
  • Slack, C., Stobie, M., Lindegger, G., Milford, C., Wassenaar, D., Strode, A., & IJsselmuiden, C. (2003). Access to treatment in HIV vaccine trials. Paper presented at the WHO-UNAIDS consultation on modalities for treatment for trial participants who become infected during HIV prevention trials, Geneva, Switzerland, 17-18 July.
  • Lindegger, G., & Slack, C. (2003). Culture and informed consent: Implications for HIV vaccine trials. Paper presented at the Full Group Meeting of the HIV Vaccine Trials Network (HVTN), Bethesda, Maryland, USA, 19-21 May.
  • Milford , C., Wassenaar, D.R., Slack, C. Strode, A., Khan, N. (2003). Identifying resources and needs of research ethics committees in Africa in preparation for HIV vaccine trials. Paper presented at the Capacity Building Workshop for African Resource Persons and Regional Ethics Committee Members involved in Ethical Review, Kampala, Uganda, 17-18 March.
  • Milford , C., Wassenaar, D.R., Slack, C., Khan, N. (2003). Resources and capacity building needs of research ethics committees in Africa in preparation for HIV vaccine trials. Paper presented at the Second Annual Meeting of African AIDS Vaccine Programme (AAVP): Strategies for the development of HIV vaccine trial sites in Africa: Challenges and Opportunities, Addis Ababa, Ethiopia. 16-18 June.
  • Slack, C., Stobie, M., Lindegger, G., Milford, C., Wassenaar, D., Strode, A., & IJsselmuiden, C. (2003). Standard of care in HIV preventive vaccine trials. Paper presented at t he Second Annual Meeting of African AIDS Vaccine Programme (AAVP): Strategies for the development of HIV vaccine trial sites in Africa: Challenges and Opportunities, Addis Ababa, Ethiopia. 16-18 June.
  • Wassenaar, D., & Richter, L., (2002). Women at the centre of the relationship between science and ethics in HIV/AIDS vaccine trials in developing countries. Keynote address at the Third Global Forum for Bioethics, Cape Town, February.
  • Lindegger, G., Richter, L., Slack, C., & Wassenaar, D., (2002). Cultural considerations in clinical trials. Paper presented at the Third Global Forum for Bioethics, Cape Town, February.
  • Lindegger, G., Slack, C., Richter, L. & Wassenaar, D, (2002). Ethical issues in HIV vaccine trials. Paper presented at the Clinical Trials in Africa conference, Johannesburg, April.
  • Van Loon, K,, Lindegger, G., & Slack, C., (2002). Informed consent: A review of South African clinical trial researchers' experiences . Paper presented at the 14 th International AIDS Conference, Barcelona, July.
  • Lindegger, G. Richter, L., Slack, C., & Wassenaar, D. (2001). Cultural considerations in clinical trials. Paper presented at the Revised Declaration of Helsinki conference, World Medical Association, Pretoria, South Africa, 27 - 28 March.
  • Lindegger, G., Slack, C., Richter, L., & Wassenaar, D. (2001). Ethical issues in recruitment of participants for clinical trials. Paper presented at the DIA Clinical trials in Africa conference, Johannesburg, 10 - 12 April.

Perinatal HIV/AIDS Research Unit

Publications

  1. Dunkle KL, Jewkes RK, Brown HC, Gray GE, McIntyre JA, Harlow. Gender-based violence, relationship power and risk of prevalent HIV infection among women attending antenatal clinics in Soweto, South Africa. The Lancet, 2004 May 1; 363 (9419): 1415-21.
  2. McClure CA, Gray G, Rybczyk GK, Wright PF. Challenges to Conducting HIV Preventative Vaccine Trials with Adolescents. J Acquir Immune Defic Syndr 2004 June 1; 36 (2): 726-733.
  3. Masemola A, Mashishi T, Khoury G, Mohube P, Mokgotho P, Vardas E, Colvin M, Zijenah L, Katzenstein D, Musonda R, Allen S, Kumwenda N, Taha T, Gray G, McIntyre J, Abdool Karim S, Sheppard HW, Gray C and the HIVNET 028 Study Team: Hierarchical Targeting of Sub-type C Human Immunodeficiency Virus Type 1 CD8+ T cells: Correlation with Viral Load. J Virol 2004 Apr; 78 (7): 3233-43.

Conference presentations

  1. Lane T, Struthers HE, Hamilton R, Gray G, McIntyre J. HIV risk behaviours among black MSM in Johannesburg, South Africa. XV International AIDS Conference, Bangkok, 2004 (WePeD6267).
  2. Mokaotle M, Martinson N, McIntyre J, Gray G, Chaisson RE. Comparing two methods of ascertaining sexually transmitted infections in HIV-infected adults. XV International AIDS Conference, Bangkok, 2004 (ThPeC7363).
  3. Vardas E, Mayaphi S, Mashego T, Mogale M, Molapo-Matsoso M, McIntyre J, Khabule V, Gray GE
    Voluntary HIV counseling and testing as a source of participants for phase I/II HIV vaccine trials in Soweto, South Africa. XV International AIDS Conference, Bangkok, 2004 (ThPeC7436).
  4. Mesesan K, Bogoshi M, Niccolai L, Gray G, McIntyre J, Vardas E.Measuring the sexual risk behavior of a cohort undergoing screening and enrollment into multiple Phase I/II HIV vaccine trials in Soweto, South Africa. XV International AIDS Conference, Bangkok, 2004 (ThPeC7438).
  5. Meddows-Taylor S, Schramm D, Gray GE, Kuhn L, Tiemessen CT. Reduced ability of newborns to produce MIP-1 and MIP-1 is associated with an increased susceptibility to perinatal HIV-1 transmission. XV International AIDS Conference, Bangkok, 2004 (MoPeA3051).
  6. Mayaphi SH, Gray G, McIntyre J, Vardas E. Challenges in recruiting participants for phase I/II HIV vaccine trials in an urban African setting. AIDS Vaccine 2004, Lausanne (P248).
  7. De Bruyn G, Molao-Matsoso M, Nuwe N, Vardas N, Corey L, Gray G.Low prevalence of helminth infections in Soweto, South Africa indicates helminths are unlikely to influence HIV vaccine evaluation. (P252).
HIV Vaccine Research Unit - Durban

KZN E News - KwaZulu-Natal AIDS Forum Newsletter

NICD
Cellular Immunology Core

Conferences

  • Sharon Shalekoff attended the XXII ISAC(International Society for Analytical Cytology) International Congress, 22-27 May, 2004.
  • Morafo V. Immunological reactivities of “optimal” subtype B-derived Epitopes in subtype C HIV-1 infected individuals reveals a high degree of epitope degeneracy. Poster presented at AIDS Vaccine 2004, Lausanne, 30 Aug - 1 Sept 2004.
  • Clive Gray was an invited speaker at AIDS Vaccine 2004, Lausanne, 30 Aug - 1 Sept 2004.

Publications

  1. Masemola A, Mashishi TN, Khoury G, Bredell H, Paximadis M, Mathebula T, Barkhan D, Puren A, Vardas E, Colvin M, Zijenah L, Katzenstein D, Musondo R, Allen S, Kumwenda N, Taha T, Gray G, McIntyre J, Abdool Karim S, Sheppard HW, Gray CM. Novel and Promiscuous Cytotoxic T Lymphocyte Epitopes in Conserved Regions of Gag Targeted by Individuals with Early Subtype C Human Immunodeficiency Virus Type-1 Infection from Southern Africa. J Immunology, In Press.

Neutralising antibody core

Participation in meetings/conferences

  • Jabulani Nhlapo and Tonie Cilliers attended the Keystone Symposia in Whistler, Canada, March-April 2004.
  • Members of the Humoral Immunity Core met with the Cape Town-based SAAVI Vaccine Group in June 2004 to discuss the need to develop HIV subtype C envelope immunogens in SAAVI and to develop stronger links with international groups working on envelope immunogens.
  • Lynn Morris , Natasha Taylor and Elin Gray attended the HVTN Full Group Meeting in Seattle, Washington, October 2004.
Publications
  1. Cilliers T, Patience T, Pillay C, Papathanasopoulos M and Morris L. Sensitivity of HIV-1 subtype C isolates to the entry inhibitor T-20. AIDS Res Hum Retro. 2004, 20: 477-482.
  2. Grobler J, Gray CM, Rademeyer C, Seoighe C, Ramjee G, Abdool-Karim SS, Morris L and Williamson C. The frequency of HIV-1 dual infection and its association with increased viral set-point in a subtype C incident cohort. J Inf Dis 2004, 190 : 1355-1359.
  3. Day JH, Grant AD, Fielding KL, Morris L, Moloi V, Charalambous S, Puren AJ, Chaisson RE, De Cock KM, Hayes RJ and Churchyard GJ. Does tuberculosis increase HIV viral load? J Inf Dis. In press.
  4. Stein L, Carrara, Norman R, Alagiozoglou L, Morris L and Sitas F. Antibodies against human Herpesvirus 8 in a selected group of South African renal transplant recipients and blood donors. Transplant Infectious Diseases. In press.
  5. Moore P, Cilliers T and Morris L. Predicted Genotypic Resistance to the Novel Entry Inhibitor, BMS-378806, among HIV-1 isolates of subtypes A to G.  AIDS. In press.
  6. Bessong P, Obi L, Cilliers T, Choge I, Phoswa M, Pillay C, Papathanasopoulos M and Morris L.  Characterization of Human Immunodeficiency Virus type 1 from a previously unexplored region of South Africa with a high HIV-1 prevalence. AIDS Res Hum Retroviruses . In Press.

Training

  • Mia Coetzer spent one month in Dr Jim Mullin’s laboratory funded by the Fogarty International Center (FIC) designing and testing algorithms for predicting coreceptor usage among HIV-1 subtype C isolates.
  • Jabulani Nhlapo spent four months in Dr Jim Robinson’s laboratory visit at Tulane Medical Center funded by FIC characterizing anti-HIV-1 monoclonal antibodies.
  • Dr Penny Moore is spending seven weeks in Dr James Binley’s laboratory at the Torrey Pines Institute for Molecular Studies, San Diego, followed by a one-week visit to Dr David Montefiori laboratory at Duke University. During this time she will be acquiring skills to enable the establishment of a molecular assay for measuring neutralising antibody responses and examining aspects of HIV entry.
  • Natasha Taylor and Isaac Choge were both awarded their Masters degrees in Virology from the University of the Witwatersrand in June 2004.

Cape Town Clinical Trials Consortium

Publications

  1. Smit J. Socio-behavioural challenges to phase III HIV vaccine trials in developing countries. In preparation.
  2. Smit J. The association between sexual risk behaviour and psychopathology. Submitted.

Presentations

  1. Mendelson F. Knowledge, attitudes and practices in a life skills programme in Masiphumelele High School. Oral presentation, XIV International AIDS Conference, Bangkok, July 2004.
  2. Jaspan H. Risk of HIV-1 acquisition in South African youth. Oral presentation, XIV International AIDS Conference, Bangkok, July 2004.
  3. Middelkoop K. An innovative community HIV education program to improve VCT uptake. Oral presentation, XIV International AIDS Conference, Bangkok, July 2004.
  4. Smit J. Who will volunteer for HIV-related research? Oral presentation, XIV International AIDS Conference, Bangkok, July 2004.
  5. Jaspan H. Children and SA Vaccine Trials. Oral presentation at the HAVEG Adolescent Ethics Workshop, Durban.
  6. Bekker LG. HIV vaccine and the South African HIV Vaccine Initiative. Antiretroviral Workshop, Johannesburg, April.
  7. Bekker LG. HIV vaccines and adolescent involvement. Youth Week at a pre-conference workshop in Bangkok.

SAAVI is supported by

Impala
Home • Partners • FAQs • Getting involved • Resources • Press releases • Useful links • Contact us • Disclaimer
Last updated: 22-Oct-2008